Clinical Trial Update: CISPLATIN + AZD-1775 In Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing cisplatin plus AZD-1775 in triple-negative metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• AZD-1775 (AZD-1775)
• CISPLATIN (cisplatin)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Triple-negative Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-11-23